From: An integrated pharmacokinetics ontology and corpus for text mining
Experimental Conditions: | Drugs | Substrate, metabolite, and inhibitor/inducer | FDA Drug Interaction Guidance, 2006 | ||
---|---|---|---|---|---|
Metabolism Enzymes | Buffer | Salt composition | Â | ||
EDTA concentration | |||||
MgCl2 concentration Cytochrome b5 concentration | Â | ||||
NADPH source | Concentration of exogenous NADPH added isocytrate dehydrogenase + NADP | Â | |||
protein | Non-recombinant enzymes | Microsomes (human liver microsomes, human intestine microsomes, S9 fraction, cytosol, whole cell lysate, hepatocytes) | Â | ||
Recombinant enzymes | Enzyme name | mg/mL or uM | Â | ||
genotype | Â | Â | |||
Transporters | Bi-Directional | CHO; Caco-2 cells; HEK-293; Hepa-RG; LLC; LLC-PK1 MDR1 cells; MDCK; MDCK-MDR1 cells; Suspension Hepatocyte | Â | ||
Transport | Â | ||||
Uptake/efflux | tumor cells, cDNA transfected cells, oocytes injected with cRNA of transporters | Â | |||
ATPase | membrane vesicles from various tissues or cells expressing P-gp, Reconstituted P-gp | Â | |||
Other factors | Pre-incubation time | Â | |||
Incubation time | Â | ||||
Quantification methods | HPLC/UV, LC/MS/MS, LC/MS, radiographic | Â | |||
Sample size | Â | ||||
 | Data Analysis | log-linear regression, plotting; and nonlinear regression |  |